Duloxetine Eli Lilly

Current Opinion in Investigational Drugs

Volumn 3, Issue 8, 2002, Pages 1217-1221

  Anttila, Sami ^a   Leinonen, Esa ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ANTIDEPRESSANT AGENT; BUSPIRONE; DOPAMINE 2 RECEPTOR; DULOXETINE; DULOXETINE OXALATE; FLUOXETINE; HISTAMINE H1 RECEPTOR; LY 206130; LY 223332; LY 223743; LY 223994; LY 227750; LY 228993; LY 248685; LY 264452; LY 267826; MUSCARINIC RECEPTOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NORADRENALIN TRANSPORTER; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PINDOLOL; SEROTONIN 1A ANTAGONIST; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; VENLAFAXINE;

ASTHENIA; BINDING AFFINITY; CLINICAL TRIAL; DEPRESSION; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFECT; DRUG MARKETING; DRUG POTENCY; DRUG POTENTIATION; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPERIMENTAL MODEL; FOOD DRUG INTERACTION; HUMAN; HYPERTENSION; INSOMNIA; META ANALYSIS; MICTURITION DISORDER; NAUSEA; NONHUMAN; REVIEW; SIDE EFFECT; SOMNOLENCE; STRESS INCONTINENCE; STRUCTURE ACTIVITY RELATION; XEROSTOMIA;

ANIMALS; ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMANS; NEUROTRANSMITTER UPTAKE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES;

EID: 0036707276     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. 119948 LY248686, a new inhibitor of serotonin and norepinephrine uptake. Wong DT, Bymaster FP, Mayle DA, Reid LR, Krushinski JH, Robertson DW Neuropsychopharmacology 1993 8 1 23-33 The article gives details of in vitro and in vivo studies of inhibition of 5-HT and NE uptake by duloxetine.
2. 159168 Effects of duloxetine, an antidepressant drug candidate, on concentrations of monoamines and their metabolites in rats and mice. Fuller RW, Hemrick Luecke SK, Snoddy HD J Pharmacol Exp Ther 1994 269 1 132-136
3. 188958 Behavioural and electrocephalographic properties of duloxetine (LY248686), a reuptake inhibitor of norepinephrine and serotonin, in mice and rats. Katoh A, Eigyo M, Ishibashi C, Naitoh Y, Takeuchi M, Ibii N, Ikeda M, Matsushita A J Pharmacol Exp Ther 1995 272 3 1067-1075
4. 208885 New drugs in the R&D pipeline. Shionogi. Pharma Jpn 1996 1488 18
5. 211405 New Drugs in the R&D Pipeline. Eli Lilly Japan. Pharma Jpn 1996 1492 14
6. 213738 Blockade of the serotonin and norepinephrine uptake processes by duloxetine: In vitro and in vivo studies in the rat brain. Kasamo K, Blier P, De Montigny C J Pharmacol Exp Ther 1996 277 1 278-286
7. 245864 Buspirone enhances duloxetine- and fluoxetine-induced increases in dialysate levels of dopamine and noradrenaline, but not serotonin, in the frontal cortex of freely moving rats. Gobert A, Rivet JM, Cistarelli JM, Millan MJ J Neurochem 1997 68 3 1326-1329
8. 259307 An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder. Berk M, Du Plessis AD, Birkett M, Richardt D Int Clin Psychopharmacol 1997 12 3 137-140 A phase II study of the antidepressant efficacy and safety of duloxetine.
9. 262560 Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat. Jackson HC, Needham AM, Hutchins LJ, Mazurkiewicz SE, Heal DJ Br J Pharmacol 1997 121 8 1758-1762
10. 1A receptors potentiates the increases in extracellular monoamines induced by duloxetine in rat hypothalamus. Engleman EA, Robertson DW, Thompson DC, Perry KW, Wong DT J Neurochem 1996 66 2 599-603
11. 278381 Simultaneous monitoring of inhibition of serotonin uptake by platelets and plasma drug concentrations following administration of duloxetine, a new antidepressant candidate, to healthy volunteers. Ishigooka J, Nagata E, Takahashi A, Sugiyama T, Uchiumi M, Tsukahara T, Murasaki M, Miura S, Oguma T, Yano Y Curr Ther Res Clin Exp 1997 58 10 679-692
12. 1A antagonist, enhances the antidepressant effect of duloxetine.
13. 300440 Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test. Reneric JP, Lucki I Psychopharmacology 1998 136 2 190-197
14. 300443 Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Beique JC, Lavoie N, De Montigny C, Debonnel G Eur J Pharmacol 1998 349 1 129-132
15. 364003 The effect of food and bedtime administration on duloxetine pharmacokinetics. Skinner MH, Skerjanec A, Seger M, Hewitt R Clin Pharmacol Ther 2000 67 2 PII-59
16. 367934 Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. Sharma A, Goldberg MJ, Cerimele BJ J Clin Pharmacol 2000 40 2 161-167 The article reports on important aspects of the pharmacokinetic and safety studies with duloxetine.
17. 375194 Chemo-enzymatic synthesis of the antidepressant duloxetine and its enantiomer. Liu H, Hoff BH, Anthonsen T Chirality 2000 12 1 26-29 Describes the synthesis of duloxetine via racemic alcohol, which was subsequently resolved using lipase B.
18. 1B receptors. Gobert A, Millan MJ Neuropsychopharmacology 1999 21 2 268-284 This study reports that pindolol may have an important effect on the actions of antidepressants.
19. 377590 Long-lasting inhibition of 5-HT uptake of platelets in subjects treated by duloxetine, a potential antidepressant. Kasahara T, Ishigooka J, Nagata E, Murasaki M, Miura S Obesity Research 1996 16 1 125-131
20. 377758 20th CINP Melbourne. Cinp Congr 1996 20th P4-P19
21. 408270 Clinical data verify that duloxetine lifts the black cloud of depression. Eli Lilly & Co Press Release 2001 May 08. A press release reporting briefly on two clinical studies, along with preclinical data on duloxetine.
22. 412025 Selected compounds in development. Eli Lilly & Co Company World Wide Website 2001 June 07
23. 416624 Biological Psychiatry - Seventh World Congress (Part II), Antidepressant Drugs, Berlin, Germany. Pivac N, Muck-Seler D
24. 426786 Lilly outlines its strategy to become the pharmaceutical growth company of the decade. Elil Lilly & Co Press Release 2001 426786
25. 429723 Lilly's duloxetine appears to lift the blues. Eli Lilly & Co Press Release 2001 November 19
26. 434250 Lilly reports on status of FDA manufacturing reinspection. Eli Lilly & Co Press Release 2001 December 19
27. 436220 Eli Lilly & Co. Hambrecht & Quist 2002 January 7-10 134
28. 444103 Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Bymaster FP, Dreshfiled-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT Neuropsychopharmacology 2001 25 6 871-880. This paper compares the affinity of duloxetine and venlafaxine for several receptors and transporters.
29. 444104 Assessment of the serotonin norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Turcotte JE, Debonnel G, De Montigny C, Hebert C, Blier P 2001 24 5 511-521
30. 449157 Duloxetine in the treatment of major depressive disorder: A double-blind clinical trial. J Clin Psychiatry 2002 63 3 225-231
31. 450920 Equity research - United States: February prescription report. Banc of America 2002 April 17
32. 450936 Eli LillY: Guidance reiterated after in-line 1Q; Growth keyed to Xigris and to FDA resolution timing. Kulju K, Beall MA, Whysall C April 16 2002
33. 450937 Eli Lilly: Lower Xigris ramp prompting estimate cuts. Rubin J, Yu N, Sone T April 16 2002
34. 451757 Data suggest the effect of Cymbalta on a broad spectrum of depression symptoms, impact on remission at starting dose. Eli Lilly & Co Press Release 2002 May 20
35. 452188 Cymbalta showed statistically significant reduction of anxiety symptoms in depressed patients. Eli Lilly & Co Press Release 2002 May 22
36. 452543 Supplement to Financial Statements, 2001. Taiwan Shionogi & Co Ltd Company Publication 2002 May 20
37. 456894 Product pipeline: Late stage compounds. Eli Lilly & Co Company World Wide Web Site 2002 April 15